Figure 7.

Human RNF10 uPeptide elicites immune response to tumor

(A) Tumor volumes were monitored weekly for 5 consecutive weeks following infusion of untreated, unpulsed, or RNF10 uPeptide pulsed DCs and T cells. (B) Tumor-infiltrating lymphocytes (TILs) were determined by tetramer staining and flow cytometry. Data are representative of two independent experiments. Percentages of dead tumor cells are shown (mean ± SD, n = 5). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, compared with untreated T cells (−). p-values were determined by two-tailed one-way ANOVA with Dunnett’s multiple-comparisons test.